Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
Public ClinicalTrials.gov record NCT05348577. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Docetaxel Versus Placebo + Docetaxel as Treatment for Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival and/or the radiographic progression free survival of study participants.
Study identification
- NCT ID
- NCT05348577
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,035 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 130 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2022 (Actual)
- Primary completion
- Mar 4, 2026 (Estimated)
- Completion
- Mar 4, 2026 (Estimated)
- Last update posted
- Jan 27, 2025
2022 – 2026
United States locations
- U.S. sites
- 37
- U.S. states
- 16
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Yuma | Arizona | 85364 | — |
| Research Site | Beverly Hills | California | 90211 | — |
| Research Site | Cerritos | California | 90703 | — |
| Research Site | Fresno | California | 93701 | — |
| Research Site | Los Angeles | California | 90095 | — |
| Research Site | Sacramento | California | 95817 | — |
| Research Site | San Francisco | California | 94115 | — |
| Research Site | Santa Barbara | California | 93105 | — |
| Research Site | Santa Monica | California | 90404 | — |
| Research Site | Santa Rosa | California | 95403 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Lakewood | Colorado | 80228 | — |
| Research Site | Littleton | Colorado | 80120 | — |
| Research Site | Baltimore | Maryland | 21201 | — |
| Research Site | Baltimore | Maryland | 21287 | — |
| Research Site | Minneapolis | Minnesota | 55404 | — |
| Research Site | Minneapolis | Minnesota | 55416 | — |
| Research Site | Hackensack | New Jersey | 07601 | — |
| Research Site | Albany | New York | 12208 | — |
| Research Site | The Bronx | New York | 10461 | — |
| Research Site | White Plains | New York | 10601 | — |
| Research Site | Toledo | Ohio | 43623 | — |
| Research Site | Portland | Oregon | 97223 | — |
| Research Site | Bala-Cynwyd | Pennsylvania | 19004-1017 | — |
| Research Site | Philadelphia | Pennsylvania | 19107 | — |
| Research Site | Philadelphia | Pennsylvania | 19111 | — |
| Research Site | Greenville | South Carolina | 29605 | — |
| Research Site | Watertown | South Dakota | 57201 | — |
| Research Site | Chattanooga | Tennessee | 37404 | — |
| Research Site | Nashville | Tennessee | 37203 | — |
| Research Site | Austin | Texas | 78731 | — |
| Research Site | Dallas | Texas | 75235 | — |
| Research Site | Houston | Texas | 77096 | — |
| Research Site | Kingwood | Texas | 77339 | — |
| Research Site | San Antonio | Texas | 78217 | — |
| Research Site | Chesapeake | Virginia | 23320 | — |
| Research Site | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 180 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05348577, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 27, 2025 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05348577 live on ClinicalTrials.gov.